# Disparities in Diagnosis, Management, and Outcomes of Hepatocellular Carcinoma: A Review of Global and Sociodemographic Factors

**Authors:** Cathy Zheng, Manuela Araque, Anthony Quiej, Keri-Ann Buchanan-Peart, Patricia D. Jones

PMC · DOI: 10.1007/s12029-026-01428-8 · Journal of Gastrointestinal Cancer · 2026-03-17

## TL;DR

This paper reviews how race, ethnicity, and socioeconomic factors affect diagnosis and outcomes of liver cancer globally.

## Contribution

The paper provides a comprehensive overview of HCC disparities using the NIMHD Research Framework.

## Key findings

- Black race and being uninsured are linked to lower HCC screening rates.
- Screening leads to earlier HCC diagnosis compared to symptom-based detection.
- Socioeconomic and geographic factors influence treatment and survival rates for HCC.

## Abstract

Hepatocellular carcinoma (HCC), the most common primary liver cancer, is a leading cause of cancer-related death. There are significant disparities in risk, receipt of screening for HCC, stage at diagnosis, receipt of treatment and survival. Differential HCC risk for HCC is driven by variation in the etiology of underlying liver disease, which varies by race, ethnicity, gender, and geographic location. Sociocultural and structural forces influence access to health care, which may limit adherence to guideline-recommended HCC screening intervals. Black race and uninsured status are associated with decreased likelihood of receiving HCC screening. These disparities in screening impact stage at presentation as patients who are diagnosed through screening present at earlier stages of disease compared to patients who are diagnosed due to symptoms. Socioeconomic status, geography, race, and ethnicity are all associated with receipt of treatment and survival after HCC diagnosis. Guided by the National Institute on Minority Health and Health Disparities (NIMHD) Research Framework, this work aims to present a comprehensive overview of disparities in HCC risk, screening, diagnosis, treatment, and outcomes.

## Linked entities

- **Diseases:** hepatocellular carcinoma (MONDO:0007256), liver cancer (MONDO:0002691)

## Full-text entities

- **Genes:** PPP1R3B (protein phosphatase 1 regulatory subunit 3B) [NCBI Gene 79660] {aka GL, PPP1R4, PTG}, PNPLA3 (patatin like domain 3, 1-acylglycerol-3-phosphate O-acyltransferase) [NCBI Gene 80339] {aka ADPN, C22orf20, iPLA(2)epsilon}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, PCLAF (PCNA clamp associated factor) [NCBI Gene 9768] {aka KIAA0101, L5, NS5ATP9, OEATC, OEATC-1, OEATC1}, NCAN (neurocan) [NCBI Gene 1463] {aka CSPG3}, GCKR (glucokinase regulator) [NCBI Gene 2646] {aka FGQTL5, GKRP}, AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}
- **Diseases:** Liver Diseases (MESH:D008107), liver dysfunction (MESH:D017093), HCV cirrhosis (MESH:D008103), inflammatory (MESH:D007249), Metabolic Dysfunction-Associated Steatohepatitis (MESH:D005234), Alcohol-associated Liver Disease (MESH:D008108), Metabolic Dysfunction (MESH:D008659), cirrhosis (MESH:D005355), Cancer (MESH:D009369), cirrhotic (MESH:D000094724), JSH (MESH:C000719191), ALD (MESH:D000326), hepatotoxic chemicals (MESH:D019966), BCLC (MESH:D006528), diabetes (MESH:D003920), insulin resistance (MESH:D007333), death (MESH:D003643), obesity (MESH:D009765)
- **Chemicals:** sorafenib (MESH:D000077157), lenvatinib (MESH:C531958), atezolizumab (MESH:C000594389), bevacizumab (MESH:D000068258), alcohol (MESH:D000438), durvalumab (MESH:C000613593), aflatoxin (MESH:D000348), TACE (-), tremelimumab (MESH:C520704)
- **Species:** hepatitis C virus [taxon 11103], Hepatitis B virus (no rank) [taxon 10407], Homo sapiens (human, species) [taxon 9606], Nicotiana tabacum (American tobacco, species) [taxon 4097]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12996431/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12996431/full.md

---
Source: https://tomesphere.com/paper/PMC12996431